[Therapeutic effect of combined administration of four drugs; vincristine, bleomycin, cyclophosphamide and prednisolone for patients with malignant lymphoma (author's transl)]. 1980

I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine

Related Publications

I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
January 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
January 1976, Zeitschrift fur Immunitatsforschung. Immunobiology,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
August 1992, International journal of hematology,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
August 1971, Cancer,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
May 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
January 2012, European journal of gynaecological oncology,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
July 1976, [Rinsho ketsueki] The Japanese journal of clinical hematology,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
January 1972, Tumori,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
January 1983, Voprosy onkologii,
I Kimura, and T Ohnoshi, and Y Nakata, and A Oka, and S Hiraki, and Y Urabe, and M Fujii, and K Hayashi, and M Sato, and M Kataoka, and R Nishihara, and S Terao, and T Mito, and T Tanaka
January 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!